Monographie - N-acetylcysteine - Stabilis 4.0

Son güncelleme :
28/04/2024

Antidot

N-acetylcysteine

Enjeksiyon

Aerosol

Göz damlası

Oral solüsyon / oral çözelti

Çözeltilerin stabilitesi

Karışımlardaki stabilitesi

Stabiliteyi etkileyen faktörler

Uyumluluk

Uygulama yöntemi

Kaynaklar

Pdf

Kimyasal yapı

Ticari isim

Ticari isim

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Acetadote	Amerika Birleşik Devletleri, Yeni Zelanda
Acetylcystein	Danimarka, Kanada
Acetylcysteine	Büyük Britanya, İran
Cilol	Hindistan
DBL acetylcysteine	Malezya, Yeni Zelanda
Fluimucil	Almanya, Ekvador, Fransa, Hollanda, İsviçre, Kolombiya, Macaristan, Polonya, Portekiz
Hidonac	Fransa, İspanya, İtalya, Malezya, Romanya
Mucare	Hindistan
Mucofrin	İtalya
Mucomelt	Hindistan
Mucomix	Hindistan
Mucosys	Hindistan
Nacel	Hindistan
Parvolex	Büyük Britanya, Kanada, Yunanistan

Kaynaklar

Enjeksiyon

Kaynaklar : N-acetylcysteine

	Tip	Yayın
1759	Dergi	Servais H, Tulkens PM. Stability and compatibility of ceftazidime administered by continuous infusion to intensive care patients. Antimicrob Agents Chemother 2001 ; 45: 2643-2647.
2076	Dergi	Dribben WH, Porto SM, Jeffords BK. Stability and microbiology of inhalant N-acetylcysteine used as an intravenous solution for the treatment of acetaminophen poisoning. Ann Emerg Med 2003 ; 42: 9-13.
2141	Dergi	Barinian N, Chanteux H, Viaene E, Servais H, Tulkens PM. Stability and compatibility study of cefepime in comparaison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units. J Antimicrob Chemother 2003 ; 51: 651-658.
2231	Dergi	de Jongh R, Hens R, Basma V, mouton JW, Tulkens PM, Carryn S. Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. J Antimicrob Chemother 2008 ; 61, 2: 382-388.
3012	Dergi	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3372	Dergi	Hanci V, Ali Kiraz H, Ömür D, Ekin S, Uyan B, Yurtlu B.S. Precipitation in Gallipoli: Sugammadex / Amiodarone & Sugammadex / Dobutamine & Sugammadex / Protamine. Rev Bras Anestesiol 2013 ; 63, 1: 163-166.
3385	Dergi	Raverdi V, Ampe E, Hecq JD, Tulkens PM. Stability and compatibility of vancomycin for administration by continuous infusion. J Antimicrob Chemother 2013 ; 68: 1179-1182.
3408	Dergi	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3766	Dergi	Forrest J.M, Hildgen P. Compatibilité de l’acétylcystéine injectable lors de son administration en Y avec d’autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.
3824	Dergi	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3964	Dergi	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
4319	Dergi	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4389	Dergi	Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G. Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévosimendan et la kétamine. Pharmactuel 2019 ;52,4:206-213
4603	Dergi	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4639	Dergi	Friciu M, Monfort A, Dubé P-A, Leclair G. Stability of N-Acetylcysteine 60 mg/mL in Extemporaneously Compounded Injectable Solutions. Can J Hosp Pharm 2021 2021;74(4):344-9
4727	Dergi	Primas N, Lano G, Brun D, Curti C, Sallée M, Sampol-Manos E, Lamy E, Bornet C, Burtey S, Vanelle P. Stability Study of Parenteral N-Acetylcysteine, and Chemical Inhibition of Its Dimerization Pharmaceuticals 2023 ;16,72

Mentions Légales